Giuseppe
Emeritus
[Source: The Journal of the American Medical Association, full text: (LINK). Extract, edited.]
Ethical Challenges of Preexposure Prophylaxis for HIV
ONLINE FIRST
Jonathan S. Jay, JD, MA; Lawrence O. Gostin, JD
Author Affiliations: O?Neill Institute for National and Global Health Law, Georgetown University Law Center, Washington, DC.
JAMA. 2012;():1-2. doi:10.1001/2012.jama.10158
Published online July 27, 2012
On July 16, 2012, emtricitabine/tenofovir (Truvada; Gilead Sciences) became the first drug approved by the US Food and Drug Administration (FDA) for preexposure prophylaxis (PrEP) of human immunodeficiency virus (HIV) for adults at high risk. Clinical trials have demonstrated that daily use of oral antiretroviral drugs can reduce the risk of HIV acquisition through sexual intercourse. With 50 000 new HIV infections per year in the United States<SUP> </SUP>and 2 million per year worldwide,<SUP> </SUP>PrEP could become a major component of ?combination prevention? along with condoms, counseling, testing, and treatment.
(?)
- ------ONLINE FIRST
Jonathan S. Jay, JD, MA; Lawrence O. Gostin, JD
Author Affiliations: O?Neill Institute for National and Global Health Law, Georgetown University Law Center, Washington, DC.
JAMA. 2012;():1-2. doi:10.1001/2012.jama.10158
Published online July 27, 2012
On July 16, 2012, emtricitabine/tenofovir (Truvada; Gilead Sciences) became the first drug approved by the US Food and Drug Administration (FDA) for preexposure prophylaxis (PrEP) of human immunodeficiency virus (HIV) for adults at high risk. Clinical trials have demonstrated that daily use of oral antiretroviral drugs can reduce the risk of HIV acquisition through sexual intercourse. With 50 000 new HIV infections per year in the United States<SUP> </SUP>and 2 million per year worldwide,<SUP> </SUP>PrEP could become a major component of ?combination prevention? along with condoms, counseling, testing, and treatment.
(?)